@prefix rdf:	<http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix ns1:	<http://linked.opendata.cz/resource/drugbank/drug/> .
@prefix ns2:	<http://linked.opendata.cz/ontology/drugbank/> .
ns1:DB00095	rdf:type	ns2:Drug ;
	ns2:description	"Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin."@en ;
	ns2:generalReferences	"#  \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8943405 # Descamps V: [Efalizumab] Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):666-78. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17053736"@en ;
	ns2:group	"approved"@en ,
		"investigational"@en ;
	ns2:halfLife	"5 days"@en ;
	ns2:indication	"For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy."@en .
@prefix owl:	<http://www.w3.org/2002/07/owl#> .
@prefix ns4:	<http://bio2rdf.org/drugbank:> .
ns1:DB00095	owl:sameAs	ns4:DB00095 .
@prefix ns5:	<http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/> .
ns1:DB00095	owl:sameAs	ns5:DB00095 .
@prefix dcterms:	<http://purl.org/dc/terms/> .
ns1:DB00095	dcterms:title	"Efalizumab"@en .
@prefix adms:	<http://www.w3.org/ns/adms#> .
@prefix ns8:	<http://linked.opendata.cz/resource/drugbank/drug/DB00095/identifier/wikipedia/> .
ns1:DB00095	adms:identifier	ns8:Efalizumab .
@prefix ns9:	<http://linked.opendata.cz/resource/drugbank/drug/DB00095/identifier/pharmgkb/> .
ns1:DB00095	adms:identifier	ns9:PA164748817 .
@prefix ns10:	<http://linked.opendata.cz/resource/drugbank/drug/DB00095/identifier/drugbank/> .
ns1:DB00095	adms:identifier	ns10:DB00095 ;
	ns2:mechanismOfAction	"Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a."@en ;
	ns2:packager	<http://linked.opendata.cz/resource/drugbank/company/271B44E8-363D-11E5-9242-09173F13E4C5> ;
	ns2:synonym	"Raptiva"@en ,
		"hu1124"@en ,
		"anti alphaL integrin"@en ,
		"antiCD11 alpha"@en .
@prefix ns11:	<http://linked.opendata.cz/ontology/sukl/drug/> .
ns1:DB00095	ns11:hasAHFSCode	<http://linked.opendata.cz/resource/AHFS/84-92-00> .
@prefix ns12:	<http://linked.opendata.cz/ontology/mesh/> .
@prefix ns13:	<http://linked.opendata.cz/resource/mesh/concept/> .
ns1:DB00095	ns12:hasConcept	ns13:M0447098 .
@prefix foaf:	<http://xmlns.com/foaf/0.1/> .
ns1:DB00095	foaf:page	<http://www.rxlist.com/cgi/generic3/raptiva.htm> ,
		<http://www.drugs.com/cdi/efalizumab.html> .
@prefix ns15:	<http://linked.opendata.cz/resource/atc/> .
ns1:DB00095	ns11:hasATCCode	ns15:L04AA21 ;
	ns2:absorption	"Average efalizumab bioavailability following subcutaneous administration was estimated at 30 to 50%."@en ;
	ns2:affectedOrganism	"Humans and other mammals"@en ;
	ns2:casRegistryNumber	"214745-43-4"@en ;
	ns2:category	"       "@en ;
	ns2:Melting-Point	<http://linked.opendata.cz/resource/drugbank/property/271B44E9-363D-11E5-9242-09173F13E4C5> .